cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Bellicum Pharmaceuticals Inc
30 own
52 watching
Current Price
$1.18
$-0.12
(-9.23%)
logo-blcm
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
10.16M
52-Week High
52-Week High
2.2
52-Week Low
52-Week Low
0.6
Average Volume
Average Volume
0.07M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
1.2551
iconMarket Capitalization10.16M
icon52-Week High2.2
icon52-Week Low0.6
iconAverage Volume0.07M
iconDividend Yield--
iconP/E Ratio1.2551
What does the Bellicum Pharmaceuticals Inc do?
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. Its clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. The company's preclinical product candidates include BPX-601, a GoCAR-T product candidate for treating solid tumors expressing the prostate stem cell antigen; and BPX-701, a T cell receptors (TCR) product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. It has a collaboration agreement with Adaptimmune Therapeutics plc to evaluate, develop, and commercialize T-cell therapies; Ospedale Pediatrico Bambino Gesu for the design and development of various T cell immunotherapies; and Academisch Ziekenhuis Leiden for research to discover and validate high-affinity TCR product candidates targeting various cancer-associated antigens. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.
Read More
How much money does Bellicum Pharmaceuticals Inc make?
News & Events about Bellicum Pharmaceuticals Inc.
Globe Newswire
8days ago
HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract on early results from a Phase 1 clinical trial for BPX-601, its lead GoCAR-T product candidate, ...
Globe Newswire
1month ago
HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced a poster presentation by the University of North Carolina Lineberger Comprehensive Cancer Center (UNC Lineberger...
Zolmax
5 months ago
StockNews.com initiated coverage on shares of Bellicum Pharmaceuticals (NASDAQ:BLCM Get Rating) in a report issued on Monday morning. The firm issued a sell rating on the biopharmaceutical companys stock. Separately, TheStreet downgraded shares of Bellicum Pharmaceuticals from a c- rating to a d- ...
Ticker Report
6 months ago
StockNews.com initiated coverage on shares of Bellicum Pharmaceuticals (NASDAQ:BLCM Get Rating) in a report published on Sunday. The firm issued a sell rating on the biopharmaceutical companys stock. Separately, TheStreet lowered shares of Bellicum Pharmaceuticals from a c- rating to ...
Ticker Report
7 months ago
StockNews.com assumed coverage on shares of Bellicum Pharmaceuticals (NASDAQ:BLCM Get Rating) in a report released on Thursday. The brokerage issued a sell rating on the biopharmaceutical companys stock. Separately, TheStreet lowered Bellicum Pharmaceuticals from a c- rating to a d- ...
Frequently Asked Questions
Frequently Asked Questions
What is Bellicum Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Bellicum Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Bellicum Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Bellicum Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Bellicum Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Bellicum Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Bellicum Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Bellicum Pharmaceuticals Inc?
plus_minus_icon
What percentage is Bellicum Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Bellicum Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.18
$-0.12
(-9.23%)
logo-blcm
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals, Inc.
$0.63
$0.03 (5.75 %)
Seres Therapeutics Inc
Seres Therapeutics Inc
$5.51
$0.08 (1.57 %)
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$39.38
$-0.37 (-0.93 %)
Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc.
$2.21
$0.07 (3.27 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals, Inc.
$0.63
$0.03 (5.75 %)
Seres Therapeutics Inc
Seres Therapeutics Inc
$5.51
$0.08 (1.57 %)
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$39.38
$-0.37 (-0.93 %)
Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc.
$2.21
$0.07 (3.27 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00